• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Trip.com, Albireo Pharma And Some Other Big Stocks Moving Higher On Thursday

    9/22/22 11:00:19 AM ET
    $ALBO
    $DB
    $HLGN
    $LI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Banks
    Finance
    Get the next $ALBO alert in real time by email

    U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording gains in today’s session.

    • Albireo Pharma, Inc. (NASDAQ:ALBO) surged 13% to $19.61. Albireo announced $115M royalty monetization agreement with Sagard.
    • Cassava Sciences, Inc. (NASDAQ:SAVA) rose 10.7% to $41.67.
    • Amprius Technologies, Inc. (NASDAQ:AMPX) gained 10% to $10.43.
    • Virtu Financial, Inc. (NASDAQ:VIRT) rose 8.7% to $23.27 after it was reported the SEC is poised to let Wall Street keep payment-for-order-flow deals.
    • Heliogen, Inc. (NASDAQ:HLGN) gained 8.3% to $1.8850.
    • Trip.com Group Limited (NASDAQ:TCOM) gained 7.7% to $26.32 after the company reported Q2 financial results.
    • Li Auto Inc. (NASDAQ:LI) rose 7.6% to $24.84 after the company announced it will host a launch event to unveil the Li L8 on Friday, September 30, 2022, ahead of schedule.
    • Silver Crest Acquisition Corporation (NASDAQ:SLCR) gained 7.2% to $9.53.
    • Deutsche Bank Aktiengesellschaft (NYSE:DB) rose 3.7% to $8.92. Deutsche Bank said its New York Branch, Deutsche Bank New York, and its affiliate Deutsche Bank Trust Company Americas have raised their prime lending from 5.50% to 6.25%.
    Get the next $ALBO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALBO
    $DB
    $HLGN
    $LI

    CompanyDatePrice TargetRatingAnalyst
    Li Auto Inc.
    $LI
    2/9/2026$14.00Neutral → Underweight
    Analyst
    Li Auto Inc.
    $LI
    1/23/2026$17.50Buy → Hold
    Jefferies
    Li Auto Inc.
    $LI
    12/4/2025$18.60Buy → Hold
    HSBC Securities
    Li Auto Inc.
    $LI
    12/1/2025$18.50Buy → Hold
    China Renaissance
    Li Auto Inc.
    $LI
    11/11/2025$19.00Neutral
    Piper Sandler
    Virtu Financial Inc.
    $VIRT
    10/28/2025$45.00Neutral → Buy
    BofA Securities
    Li Auto Inc.
    $LI
    9/3/2025$30.50Outperform → Buy
    Daiwa Securities
    Li Auto Inc.
    $LI
    8/28/2025$26.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $ALBO
    $DB
    $HLGN
    $LI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BYLVAY issued to ALBIREO PHARMA INC

    Submission status for ALBIREO PHARMA INC's drug BYLVAY (ORIG-1) with active ingredient ODEVIXIBAT has changed to 'Approval' on 07/20/2021. Application Category: NDA, Application Number: 215498, Application Classification: Type 1 - New Molecular Entity

    7/21/21 11:28:05 AM ET
    $ALBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $DB
    $HLGN
    $LI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-President & Co-COO Molluso Joseph sold $7,776,420 worth of shares (200,000 units at $38.88), decreasing direct ownership by 38% to 326,585 units (SEC Form 4)

    4 - Virtu Financial, Inc. (0001592386) (Issuer)

    2/20/26 5:28:10 PM ET
    $VIRT
    Investment Bankers/Brokers/Service
    Finance

    EVP Cavoli Stephen sold $1,104,657 worth of shares (28,370 units at $38.94), decreasing direct ownership by 20% to 116,191 units (SEC Form 4)

    4 - Virtu Financial, Inc. (0001592386) (Issuer)

    2/18/26 8:43:27 PM ET
    $VIRT
    Investment Bankers/Brokers/Service
    Finance

    EVP Cavoli Stephen sold $2,728,560 worth of shares (71,630 units at $38.09), decreasing direct ownership by 33% to 144,561 units (SEC Form 4)

    4 - Virtu Financial, Inc. (0001592386) (Issuer)

    2/13/26 5:25:50 PM ET
    $VIRT
    Investment Bankers/Brokers/Service
    Finance

    $ALBO
    $DB
    $HLGN
    $LI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ALBO
    $DB
    $HLGN
    $LI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ALBO
    $DB
    $HLGN
    $LI
    SEC Filings

    View All

    Cassava Announces Closure of U.S. Department of Justice Investigation

    AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.). That indictment was dismissed with prejudice by DOJ on October 23, 2025. As previously disclosed, the Company reached a settlement with the U.S. Securities an

    2/19/26 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trip.com Group Limited to Report Fourth Quarter and Full Year of 2025 Financial Results on February 25, 2026 U.S. Time

    SINGAPORE, Feb. 9, 2026 /PRNewswire/ -- Trip.com Group Limited (NASDAQ:TCOM, HKEX: 9961)), a leading one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours and corporate travel management, will announce its fourth quarter and full year of 2025 financial results on Wednesday, February 25, 2026, U.S. Time, after the market closes. Trip.com Group's management team will host a conference call at 7:00 PM U.S. Eastern Time on February 25, 2026 (or 8:00 AM on February 26, 2026 in the Hong Kong Time) following the announcement. The conference call will be available on Webcast live and replay at: http://investors.trip.com. The call will be archived fo

    2/9/26 5:00:00 AM ET
    $TCOM
    Real Estate

    Li Auto Inc. January 2026 Delivery Update

    BEIJING, China, Feb. 01, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:LI, HKEX: 2015)), a leader in China's new energy vehicle market, today announced that it delivered 27,668 vehicles in January 2026. As of January 31, 2026, Li Auto's cumulative deliveries reached 1,567,883. In January, Li Auto rolled out OTA update version 8.2 to users, introducing 40 new features and 25 experience optimizations, delivering comprehensive upgrades to its assisted driving, smart space, and smart electric experiences. The reinforced VLA Driver large model launched alongside the system update has significantly improved its ability to reason about and understand the physical wor

    1/31/26 9:00:00 PM ET
    $LI
    Auto Manufacturing
    Industrials

    Li Auto downgraded by Analyst with a new price target

    Analyst downgraded Li Auto from Neutral to Underweight and set a new price target of $14.00

    2/9/26 7:00:29 AM ET
    $LI
    Auto Manufacturing
    Industrials

    Li Auto downgraded by Jefferies with a new price target

    Jefferies downgraded Li Auto from Buy to Hold and set a new price target of $17.50

    1/23/26 8:13:46 AM ET
    $LI
    Auto Manufacturing
    Industrials

    Li Auto downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Li Auto from Buy to Hold and set a new price target of $18.60

    12/4/25 8:27:48 AM ET
    $LI
    Auto Manufacturing
    Industrials

    SEC Form 10-K filed by Virtu Financial Inc.

    10-K - Virtu Financial, Inc. (0001592386) (Filer)

    2/20/26 5:09:48 PM ET
    $VIRT
    Investment Bankers/Brokers/Service
    Finance

    Cassava Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

    2/19/26 8:15:27 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-N filed by Deutsche Bank AG

    F-N - DEUTSCHE BANK AKTIENGESELLSCHAFT (0001159508) (Subject)

    2/10/26 3:43:44 PM ET
    $DB
    Major Banks
    Finance

    $ALBO
    $DB
    $HLGN
    $LI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $414,000 worth of shares (150,000 units at $2.76) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/24/25 4:02:17 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $201,809 worth of shares (73,385 units at $2.75) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/20/25 5:39:26 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $DB
    $HLGN
    $LI
    Leadership Updates

    Live Leadership Updates

    View All

    Cassava Reports Q3 2025 Financials Results and Provides Business Update

    Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende

    11/12/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

    AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value creation for pre-commercial and commercial biotechnology and life science companies including Reata Pharmaceuticals, Inc. (acquired by Biogen Inc.), Geron Corporation,

    10/22/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Reports Q2 2025 Financials Results and Provides Business Update

    Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced neuroscience leaders to guide the clinical development strategy for simufilamAdvanced settlement negotiations ongoing to resolve certain securities litigation; $31.25 million estimated loss contingency recorded in Q2 for resolution$112.4 million in cash and cash equivalents at June 30, 2025 AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for c

    8/14/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $DB
    $HLGN
    $LI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Virtu Financial Inc.

    SC 13G/A - Virtu Financial, Inc. (0001592386) (Subject)

    11/14/24 11:00:39 AM ET
    $VIRT
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Trip.com Group Limited

    SC 13G/A - Trip.com Group Ltd (0001269238) (Subject)

    11/13/24 12:49:26 PM ET
    $TCOM
    Real Estate

    SEC Form SC 13G filed by Virtu Financial Inc.

    SC 13G - Virtu Financial, Inc. (0001592386) (Subject)

    11/12/24 10:34:15 AM ET
    $VIRT
    Investment Bankers/Brokers/Service
    Finance

    $ALBO
    $DB
    $HLGN
    $LI
    Financials

    Live finance-specific insights

    View All

    Trip.com Group Limited to Report Fourth Quarter and Full Year of 2025 Financial Results on February 25, 2026 U.S. Time

    SINGAPORE, Feb. 9, 2026 /PRNewswire/ -- Trip.com Group Limited (NASDAQ:TCOM, HKEX: 9961)), a leading one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours and corporate travel management, will announce its fourth quarter and full year of 2025 financial results on Wednesday, February 25, 2026, U.S. Time, after the market closes. Trip.com Group's management team will host a conference call at 7:00 PM U.S. Eastern Time on February 25, 2026 (or 8:00 AM on February 26, 2026 in the Hong Kong Time) following the announcement. The conference call will be available on Webcast live and replay at: http://investors.trip.com. The call will be archived fo

    2/9/26 5:00:00 AM ET
    $TCOM
    Real Estate

    Virtu Announces Fourth Quarter 2025 Results

    NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NYSE:VIRT), a leading provider of financial services and products that leverages cutting edge technology to deliver innovative, transparent trading solutions to its clients and liquidity to the global markets, today reported results for the fourth quarter ended December 31, 2025. Fourth Quarter and Full Year Selected Highlights Fourth Quarter 2025: Net income of $280.6 million; Normalized Adjusted Net Income1 of $294.5 millionBasic and diluted earnings per share of $1.54; Normalized Adjusted EPS1 of $1.85Total revenues of $969.9 million; Trading income, net, of $664.9 million; Net income Margin of 28.9%2 Adjusted Net Tra

    1/29/26 6:50:00 AM ET
    $VIRT
    Investment Bankers/Brokers/Service
    Finance

    Virtu Financial to Host Conference Call Announcing Fourth Quarter 2025 Results on Thursday, January 29, 2026

    NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NYSE:VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to the global markets, will announce its results for the fourth quarter of 2025 on Thursday, January 29, 2026, before the US market open. Virtu will host a conference call to discuss the company's financial results at 8:00 AM (ET). A live webcast of the event will be available and archived on the Investor Relations section of the company's website at https://ir.virtu.com/events-presentations. The call will be open to the public. About Virtu Financial, In

    1/14/26 9:41:00 AM ET
    $VIRT
    Investment Bankers/Brokers/Service
    Finance